暂无数据
代码股票名称
最新价涨跌额涨跌幅成交量成交额今开昨收最高最低总市值流通市值总股本流通股本5日涨跌幅10日涨跌幅20日涨跌幅60日涨跌幅120日涨跌幅250日涨跌幅年初至今涨跌幅股息率TTM换手率市盈率TTM市盈率(静)振幅所属行业
美股市场个股详情
SNSE Sensei Biotherapeutics
- 1.641
- -0.009-0.56%
交易中 05/03 09:36 (美东)
4115.28万总市值-1344市盈率TTM
1.770最高价1.630最低价10.62万股成交量1.760今开1.650昨收18.15万成交额0.65%换手率亏损市盈率(静)2508.10万总股本1.92052周最高0.63市净率2694.26万流通值0.51052周最低--股息TTM1642.04万流通股26.500历史最高--股息率TTM8.47%振幅0.510历史最低1.708平均价1股每手
盘中分时
- 5日
- 日K
- 周K
- 月K
- 季K
- 年K
资金分布
单位: --
资金流向
实时日周月
暂无数据
新闻
CTMX、HSDT 和 SNSE 是盘前涨幅最大的股票
JAGX、SNSE 和 BON 是午间推动者
周四盘中交易时段，12只医疗保健类股走势
在周四的例会中，GainersEmergent BioSolutions（纽约证券交易所代码：EBS）股价上涨了98.4％，至3.83美元。该公司的市值为2.06亿美元。该公司公布了第一季度的收益
Sensei Biotherapeutics 将在 2024 年 ASCO 年会上公布 SNS-101 I 期剂量递增研究的主要临床数据
波士顿，2024年4月24日（GLOBE NEWSWIRE）——Sensei Biotherapeutics, Inc.（纳斯达克股票代码：SNSE）是一家临床阶段的免疫肿瘤学公司，专注于下一代疗法的发现和开发
周一盘后交易时段，12只医疗保健股走势
在周一的盘后交易中，GainersNuwellis（纳斯达克股票代码：NUWE）股价上涨46.8％，至0.48美元。该公司的市值为320万美元。Sensei Biotherapeutics（纳斯达克股票代码：SNSE）股票上涨7.42％，至
Sensei Biotherapeutics扩大与前首席财务官的关系
评论
$Sensei Biotherapeutics(SNSE.US$ can we push pass 1.9 and go 2 onwards
2
1
Biotherapeutics Company Announces Revolutionary Cancer Treatment Development
Revolutionary Cancer Treatment on the Horizon: How Sensei Biotherapeutics' SNS-101 Could Change the Game.
In the ongoing battle against cancer, groundbreaking research and innovative treatments are the beacons of hope for patients worldwide. One such beacon shines brightly from the laboratories of Sensei Biotherapeutics, Inc., a clinical-stage immuno-oncology company dedicated to the discovery and development of next-gen...
In the ongoing battle against cancer, groundbreaking research and innovative treatments are the beacons of hope for patients worldwide. One such beacon shines brightly from the laboratories of Sensei Biotherapeutics, Inc., a clinical-stage immuno-oncology company dedicated to the discovery and development of next-gen...
$Sensei Biotherapeutics(SNSE.US$
NEWS
Sensei Biotherapeutics, Inc. (SNSE) announces the publication of a research paper in Nature Communications detailing the development of SNS-101, a pH-sensitive monoclonal antibody targeting VISTA to suppress T-cell activation in cancer patients. The paper highlights the unique mechanism of SNS-101 in mitigating CRS risk and maintaining a favorable safety profile, potentially revolutionizing VISTA-directed immunotherapy.
NEWS
Sensei Biotherapeutics, Inc. (SNSE) announces the publication of a research paper in Nature Communications detailing the development of SNS-101, a pH-sensitive monoclonal antibody targeting VISTA to suppress T-cell activation in cancer patients. The paper highlights the unique mechanism of SNS-101 in mitigating CRS risk and maintaining a favorable safety profile, potentially revolutionizing VISTA-directed immunotherapy.
The appointment of Krebs is viewed as a positive step for Sensei, as it may further the company's capabilities in strategic alliances, pipeline expansion and program development. Her extensive experience could be valuable to the company's growth.
阅读更多
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅
MitchBrannon : it does look like it could break if it gets over 1.85